The safety of our study participants and study staff is our number one priority, especially during these changing times. We are staying on top of the latest COVID-19 developments and working to deploy ways to maintain the safety of everyone involved, while keeping the study on track. Participants are encouraged to contact their study site directly for the latest updates or with any questions or concerns.
Thanks to the personal contribution and dedication of our patients, as well as that of the clinicians and support staff, we are closer than ever to finding a treatment for this chronic and life-threatening condition.
NASH is a serious liver disease that has become increasingly
common. It can lead to liver failure,
the need for a liver
transplant, cancer, and even death.
Because of the vast number of people who suffer from this condition, finding a treatment has never been more important. The REGENERATE trial is one of the first Phase III trials to try to address this challenge.
Nonalcoholic Steatohepatitis (NASH) is a chronic condition in which the buildup of fat, liver cell injury, and inflammation in the liver may eventually lead to scarring called fibrosis which may advance and require a liver transplant. It is currently the second leading cause of liver transplant in the U.S.
Because people with NASH experience nonspecific symptoms, the disease can progress for years without a diagnosis.
Currently, there are no medications approved for the treatment of NASH. But researchers are working toward changing that by conducting clinical trials.
Use ClinTrialConnect to learn more about NASH and the REGENERATE study, communicate with study sites, and download and share resources with loved ones.
